SION
Sionna Therapeutics, Inc.
Price Chart
Latest Quote
$37.30
+0.57 (+1.55%)
Current Price
| Previous Close | $36.73 |
| Open | $38.28 |
| Day High | $38.55 |
| Day Low | $36.63 |
| Volume | 596,377 |
Stock Information
| Shares Outstanding | 45.15M |
| Total Debt | $8.38M |
| Cash Equivalents | $216.15M |
| Net Income | $-85.56M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.68B |
| EPS (TTM) | $-1.86 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.36B |
| Income | $-85.56M |
| Book/sh | $6.39 |
| Cash/sh | $4.79 |
| Employees | 59 |
Financial Ratios
| Quick Ratio | 22.11 |
| Current Ratio | 22.60 |
| Debt/Eq | 2.91 |
Returns & Margins
| ROA | -18.33% |
| ROE | -26.74% |
Ownership
| Insider Ownership | 6.85% |
| Institutional Ownership | 100.27% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -13.31 |
| P/B | 5.83 |
Analyst Data
| Recommendation | buy |
| Target Price | $51.60 |
Technical Indicators
| SMA20 | $38.00 |
| SMA50 | $39.91 |
| SMA200 | $37.20 |
| RSI | 35.05 |
| ATR | 2.7821 |
| Shares Float | 16.80M |
| Short Float | 16.68% |
| Short Ratio | 12.48 |
| Rel Volume | 2.00 |
Performance History
| Week | +3.47% |
| Month | -1.01% |
| Quarter | +5.10% |
| 6 Months | -13.03% |
| YTD | -4.87% |
| Year | +169.31% |
| 10 Years | +49.20% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $37.30 | 736,800 |
| 2026-06-17 | $36.73 | 406,700 |
| 2026-06-16 | $34.75 | 375,100 |
| 2026-06-15 | $36.00 | 278,600 |
| 2026-06-12 | $35.92 | 189,600 |
| 2026-06-11 | $36.05 | 399,000 |
| 2026-06-10 | $34.03 | 316,900 |
| 2026-06-09 | $33.69 | 320,200 |
| 2026-06-08 | $33.51 | 423,800 |
| 2026-06-05 | $35.37 | 461,300 |
| 2026-06-04 | $37.78 | 362,900 |
| 2026-06-03 | $36.70 | 319,300 |
| 2026-06-02 | $36.48 | 537,800 |
| 2026-06-01 | $40.90 | 400,100 |
| 2026-05-29 | $42.82 | 645,300 |
| 2026-05-28 | $42.80 | 416,000 |
| 2026-05-27 | $43.43 | 185,500 |
| 2026-05-26 | $42.88 | 188,800 |
| 2026-05-22 | $41.13 | 182,600 |
| 2026-05-21 | $41.75 | 236,900 |
| 2026-05-20 | $39.50 | 392,300 |
| 2026-05-19 | $37.68 | 313,500 |
About Sionna Therapeutics, Inc.
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
đ° Latest News
Assessing Sionna Therapeutics (SION) Valuation After A Mixed Period For Recent Share Price Returns
Simply Wall St. âĸ 2026-06-11T09:12:05Z
Wedbush Initiates Coverage of Sionna Therapeutics (SION)
Insider Monkey âĸ 2026-05-14T16:52:34Z
A Look At Sionna Therapeutics (SION) Valuation After Its Strong 1 Year Return And Premium P/B Ratio
Simply Wall St. âĸ 2026-05-05T14:11:29Z
Sionna Insider Sells $2.5 Million in Stock Amid 215% Surge, but Here's What Investors Should Watch
Motley Fool âĸ 2026-04-27T19:49:52Z
Sionna Chief Legal Officer Cashed Out Her Shares. Her Options Are Another Story
Motley Fool âĸ 2026-03-31T01:28:05Z
Sionna Stock Is Up 144% This Past Year. Is the Biotech a Buy as One Fund Makes a $7 Million Bet?
Motley Fool âĸ 2026-03-18T15:49:37Z
This Investor Sold $5 Million of a Biotech Stock Up 118% in a Year, but Here's Why It Still Seems Bullish on Shares
Motley Fool âĸ 2026-03-15T22:27:41Z
Assessing Sionna Therapeutics (SION) Valuation As Premium P/B Meets Cooling Share Price Momentum
Simply Wall St. âĸ 2026-02-27T16:09:41Z
Sionna Therapeutics Maps Mid-2026 CF Catalysts, Highlights NBD1 Stabilizers at Guggenheim Summit
MarketBeat âĸ 2026-02-15T09:41:12Z
Sionna Therapeutics Chief Legal Officer Caps Off Strong 2025 with Sale of Over 10,000 Shares
Motley Fool âĸ 2026-01-13T01:32:40Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $88,982,000 | $70,556,000 | $50,333,000 | $41,372,000 |
| Other Income Expense | $419,000 | $698,000 | $301,000 | - |
| Other Non Operating Income Expenses | $419,000 | $698,000 | $301,000 | - |
| Net Non Operating Interest Income Expense | $13,295,000 | $8,170,000 | $2,769,000 | $1,132,000 |
| Operating Expense | $88,982,000 | $70,556,000 | $50,333,000 | $41,372,000 |
| General And Administrative Expense | $28,719,000 | $13,268,000 | $9,707,000 | $6,767,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-75,268,000 | $-61,688,000 | $-47,263,000 | $-40,240,000 |
| Net Interest Income | $13,295,000 | $8,170,000 | $2,769,000 | $1,132,000 |
| Interest Income | $13,295,000 | $8,170,000 | $2,769,000 | $1,132,000 |
| Normalized Income | $-75,268,000 | $-61,688,000 | $-47,263,000 | $-40,240,000 |
| Net Income From Continuing And Discontinued Operation | $-75,268,000 | $-61,688,000 | $-47,263,000 | $-40,240,000 |
| Total Operating Income As Reported | $-88,982,000 | $-70,556,000 | $-50,333,000 | $-41,372,000 |
| Net Income Common Stockholders | $-75,268,000 | $-61,688,000 | $-47,263,000 | $-40,240,000 |
| Net Income | $-75,268,000 | $-61,688,000 | $-47,263,000 | $-40,240,000 |
| Net Income Including Noncontrolling Interests | $-75,268,000 | $-61,688,000 | $-47,263,000 | $-40,240,000 |
| Net Income Continuous Operations | $-75,268,000 | $-61,688,000 | $-47,263,000 | $-40,240,000 |
| Pretax Income | $-75,268,000 | $-61,688,000 | $-47,263,000 | $-40,240,000 |
| Interest Income Non Operating | $13,295,000 | $8,170,000 | $2,769,000 | $1,132,000 |
| Operating Income | $-88,982,000 | $-70,556,000 | $-50,333,000 | $-41,372,000 |
| Per Share | ||||
| Diluted EPS | $-1.88 | $-1.45 | $-1.70 | $-2.32 |
| Basic EPS | $-1.88 | $-1.45 | $-1.70 | $-2.32 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-88,335,000 | $-69,888,000 | $-49,750,000 | $-41,250,000 |
| Reconciled Depreciation | $647,000 | $668,000 | $583,000 | $122,000 |
| EBITDA (Bullshit earnings) | $-88,335,000 | $-69,888,000 | $-49,750,000 | $-41,250,000 |
| EBIT | $-88,982,000 | $-70,556,000 | $-50,333,000 | $-41,372,000 |
| Diluted Average Shares | $39,962,163 | $42,444,742 | $27,797,075 | $17,332,468 |
| Basic Average Shares | $39,962,163 | $42,444,742 | $27,797,075 | $17,332,468 |
| Diluted NI Availto Com Stockholders | $-75,268,000 | $-61,688,000 | $-47,263,000 | $-40,240,000 |
| Research And Development | $60,263,000 | $57,288,000 | $40,626,000 | $34,605,000 |
| Selling General And Administration | $28,719,000 | $13,268,000 | $9,707,000 | $6,767,000 |
| Other Gand A | $9,821,000 | $5,426,000 | $3,783,000 | $2,283,000 |
| Salaries And Wages | $18,898,000 | $7,842,000 | $5,924,000 | $4,484,000 |
Fetched: 2026-06-19
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $306,833,000 | $-163,713,000 | $-114,881,000 | $-69,924,000 |
| Total Assets | $325,953,000 | $185,752,000 | $51,945,000 | $87,369,000 |
| Total Non Current Assets | $84,534,000 | $34,759,000 | $12,738,000 | $3,536,000 |
| Other Non Current Assets | $963,000 | $3,956,000 | $1,006,000 | $962,000 |
| Investmentin Financial Assets | $74,420,000 | $20,505,000 | $0 | - |
| Current Assets | $241,419,000 | $150,993,000 | $39,207,000 | $83,833,000 |
| Other Current Assets | $5,537,000 | $3,455,000 | $686,000 | $1,223,000 |
| Cash Cash Equivalents And Short Term Investments | $235,882,000 | $147,538,000 | $38,521,000 | $82,610,000 |
| Cash And Cash Equivalents | $58,451,000 | $37,788,000 | $38,521,000 | $54,837,000 |
| Debt | ||||
| Total Debt | $8,677,000 | $9,749,000 | $10,477,000 | $0 |
| Long Term Debt And Capital Lease Obligation | $7,408,000 | $8,677,000 | $9,749,000 | $0 |
| Current Debt And Capital Lease Obligation | $1,269,000 | $1,072,000 | $728,000 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $19,120,000 | $349,465,000 | $166,826,000 | $157,293,000 |
| Total Non Current Liabilities Net Minority Interest | $7,408,000 | $339,045,000 | $158,789,000 | $149,040,000 |
| Current Liabilities | $11,712,000 | $10,420,000 | $8,037,000 | $8,253,000 |
| Other Current Liabilities | $6,000 | - | - | - |
| Payables And Accrued Expenses | $5,697,000 | $6,376,000 | $4,197,000 | $6,300,000 |
| Payables | $769,000 | $1,186,000 | $719,000 | $557,000 |
| Accounts Payable | $769,000 | $1,186,000 | $719,000 | $557,000 |
| Equity | ||||
| Common Stock Equity | $306,833,000 | $-163,713,000 | $-114,881,000 | $-69,924,000 |
| Total Equity Gross Minority Interest | $306,833,000 | $-163,713,000 | $-114,881,000 | $-69,924,000 |
| Stockholders Equity | $306,833,000 | $-163,713,000 | $-114,881,000 | $-69,924,000 |
| Gains Losses Not Affecting Retained Earnings | $540,000 | $368,000 | $0 | $-16,000 |
| Other Equity Adjustments | $540,000 | $368,000 | - | $-16,000 |
| Retained Earnings | $-256,354,000 | $-181,086,000 | $-119,398,000 | $-72,135,000 |
| Preferred Securities Outside Stock Equity | $0 | $330,368,000 | $149,040,000 | $149,040,000 |
| Preferred Stock Equity | - | $330,368,000 | $149,040,000 | $149,040,000 |
| Other | ||||
| Ordinary Shares Number | $44,723,585 | $42,444,742 | $42,444,742 | $42,444,742 |
| Share Issued | $44,723,585 | $42,444,742 | $42,444,742 | $42,444,742 |
| Tangible Book Value | $306,833,000 | $-163,713,000 | $-114,881,000 | $-69,924,000 |
| Invested Capital | $306,833,000 | $-163,713,000 | $-114,881,000 | $-69,924,000 |
| Working Capital | $229,707,000 | $140,573,000 | $31,170,000 | $75,580,000 |
| Capital Lease Obligations | $8,677,000 | $9,749,000 | $10,477,000 | $0 |
| Total Capitalization | $306,833,000 | $-163,713,000 | $-114,881,000 | $-69,924,000 |
| Additional Paid In Capital | $562,602,000 | $17,000,000 | $4,515,000 | $2,225,000 |
| Capital Stock | $45,000 | $5,000 | $2,000 | $2,000 |
| Common Stock | $45,000 | $5,000 | $2,000 | $2,000 |
| Preferred Stock | $0 | $0 | $149,040,000 | $149,040,000 |
| Long Term Capital Lease Obligation | $7,408,000 | $8,677,000 | $9,749,000 | $0 |
| Current Capital Lease Obligation | $1,269,000 | $1,072,000 | $728,000 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | $4,740,000 | $2,972,000 | $3,112,000 | $1,953,000 |
| Current Accrued Expenses | $4,928,000 | $5,190,000 | $3,478,000 | $5,743,000 |
| Investments And Advances | $74,420,000 | $20,505,000 | $0 | - |
| Available For Sale Securities | $74,420,000 | $20,505,000 | - | - |
| Net PPE | $9,151,000 | $10,298,000 | $11,732,000 | $2,574,000 |
| Accumulated Depreciation | $-2,122,000 | $-1,571,000 | $-914,000 | $-344,000 |
| Gross PPE | $11,273,000 | $11,869,000 | $12,646,000 | $2,918,000 |
| Leases | $1,920,000 | $1,854,000 | $1,854,000 | $0 |
| Other Properties | $8,501,000 | $9,293,000 | $9,954,000 | $617,000 |
| Machinery Furniture Equipment | $852,000 | $722,000 | $722,000 | $0 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $177,431,000 | $109,750,000 | $0 | $27,773,000 |
| Construction In Progress | - | $0 | $116,000 | $2,301,000 |
Fetched: 2026-06-19
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-66,674,000 | $-52,814,000 | $-44,815,000 | $-37,942,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-66,297,000 | $-52,787,000 | $-43,699,000 | $-36,068,000 |
| Cash Flow From Continuing Operating Activities | $-66,297,000 | $-52,787,000 | $-43,699,000 | $-36,068,000 |
| Investing Activities | ||||
| Capital Expenditure | $-377,000 | $-27,000 | $-1,116,000 | $-1,874,000 |
| Investing Cash Flow | $-118,749,000 | $-126,913,000 | $27,352,000 | $-29,263,000 |
| Cash Flow From Continuing Investing Activities | $-118,749,000 | $-126,913,000 | $27,352,000 | $-29,263,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $202,071,000 | $181,328,000 | $0 | $110,791,000 |
| Financing Cash Flow | $205,710,000 | $178,967,000 | $31,000 | $110,855,000 |
| Cash Flow From Continuing Financing Activities | $205,710,000 | $178,967,000 | $31,000 | $110,855,000 |
| Net Preferred Stock Issuance | $0 | $181,328,000 | $0 | $110,791,000 |
| Preferred Stock Issuance | $0 | $181,328,000 | $0 | $110,791,000 |
| Net Common Stock Issuance | $202,071,000 | $0 | - | - |
| Common Stock Issuance | $202,071,000 | $0 | - | - |
| Net Other Financing Charges | - | $-2,502,000 | - | - |
| Other | ||||
| End Cash Position | $59,414,000 | $38,750,000 | $39,483,000 | $55,799,000 |
| Beginning Cash Position | $38,750,000 | $39,483,000 | $55,799,000 | $10,275,000 |
| Changes In Cash | $20,664,000 | $-733,000 | $-16,316,000 | $45,524,000 |
| Proceeds From Stock Option Exercised | $3,639,000 | $141,000 | $31,000 | $64,000 |
| Net Investment Purchase And Sale | $-118,372,000 | $-126,886,000 | $28,468,000 | $-27,389,000 |
| Sale Of Investment | $206,653,000 | $55,955,000 | $52,000,000 | $13,000,000 |
| Purchase Of Investment | $-325,025,000 | $-182,841,000 | $-23,532,000 | $-40,389,000 |
| Net PPE Purchase And Sale | $-377,000 | $-27,000 | $-1,116,000 | $-1,874,000 |
| Purchase Of PPE | $-377,000 | $-27,000 | $-1,116,000 | $-1,874,000 |
| Change In Working Capital | $-2,652,000 | $-3,075,000 | $-783,000 | $2,764,000 |
| Change In Other Current Liabilities | $-2,128,000 | $-1,897,000 | $-172,000 | $0 |
| Change In Other Current Assets | $0 | $35,000 | $0 | - |
| Change In Payables And Accrued Expense | $1,558,000 | $1,547,000 | $-944,000 | $3,517,000 |
| Change In Accrued Expense | $1,975,000 | $1,080,000 | $-1,106,000 | $5,031,000 |
| Change In Payable | $-417,000 | $467,000 | $162,000 | $-1,514,000 |
| Change In Account Payable | $-417,000 | $467,000 | $162,000 | $-1,514,000 |
| Change In Prepaid Assets | $-2,082,000 | $-2,760,000 | $333,000 | $-753,000 |
| Other Non Cash Items | $1,962,000 | $10,601,000 | $2,184,000 | - |
| Stock Based Compensation | $12,066,000 | $3,708,000 | $2,259,000 | $1,686,000 |
| Amortization Of Securities | $-3,052,000 | $-3,001,000 | $-679,000 | $-400,000 |
| Depreciation Amortization Depletion | $647,000 | $668,000 | $583,000 | $122,000 |
| Depreciation And Amortization | $647,000 | $668,000 | $583,000 | $122,000 |
| Depreciation | $647,000 | $668,000 | $583,000 | $122,000 |
| Net Income From Continuing Operations | $-75,268,000 | $-61,688,000 | $-47,263,000 | $-40,240,000 |
Fetched: 2026-06-19